Young doctor working

2014 Financial results

Pascal Soriot, Chief Executive Officer, commenting on the results, said:

“2014 was a remarkable year for AstraZeneca. We achieved a record six product approvals as we accelerated our pipeline across all main therapy areas. Alongside this, we delivered four quarters of revenue growth, with growth platforms now contributing over half of our revenues. Our strong performance in Emerging Markets is a particular highlight, with China becoming our second largest national market, while the delay in the introduction of Nexium generics in the US helped to direct additional investment towards our launch brands and our rapidly advancing pipeline.

“Our guidance for 2015 reflects our focus on creating value by investing in our new brands and exciting pipeline while we continue improving productivity to protect our profitability in the face of patent expiries. With the depth of our science and the momentum we have built across our organisation, we are on track to return to growth by 2017 and are well positioned to deliver our long-term goals.”

Teleconference replay

A recording of the analyst conference and Q&A session will be available from 17:00GMT Thursday 5th February until 15:00GMT Wednesday 18th February, on the following numbers:

LocationNumberConference ID
UK local 0800 953 1533 75172849
US (freephone) 1 866 247 4222 75172849
International +44 1452 55 00 00 75172849


Keeping investors in touch

Download our iPad app now from the app store

The AstraZeneca Investor Relations iPad app provides instant access to our latest news, webcasts and presentations, events and leadership videos.

Download and install from the iTunes store